CXCL13 and breast cancer: In RCB II/III breast cancer, patients with high expression of EV_APRIL (67.4% vs. 84.0%; p = 0.049), EV_CXCL13 (67.2% vs. 89.5%; p = 0.015), and EV_VEGF-A (66.0% vs. 87.0%; p = 0.020) had shorter OS than those with low cytokine expressions (Figure 4C).